Alternative strategies are urgently required to combat the rise of high-risk carbapenem-resistant Klebsiella pneumoniae (CRKP), including bla-positive strains that produce carbapenemase enzymes, which deactivate beta-lactam antibiotics and result in poor treatment outcomes. In this study, we isolated a bacteriophage BPK01, targeting a high-risk strain of Klebsiella pneumoniae (carbapenem-resistant, bla-positive, ST147, capsular type K64, biofilm former). BPK01 demonstrated strong lytic activity (84%) against a panel of genetically characterized CRKP strains (n = 59) from clinical specimens, including pus, urine, sputum, blood, and tracheal aspirates. BPK01 was classified as a Caudoviricetes phage, exhibiting a burst size of 220 virions and a short latent period of 10 min. It demonstrated stability across a range of conditions (temperature, pH, and organic solvents) and effectively disrupted biofilms on silicone catheters. In vivo, BPK01 improved survival rates in the Galleria mellonella infection model and reduced bacterial burden in a murine bacteremia model, underscoring its therapeutic potential. Subsequently, we developed a hydrogel by incorporating BPK01 into a chitosan biopolymer, which demonstrated efficient lytic activity (spot assay, scanning electron microscopy, time kill assay) against CRKP pathogens, stability of biological activity for 6 months of storage, and controlled release kinetics, with the mathematical model Korsmeyer - Peppas being the best fit (R = 0.9962). The hydrogel expedited the healing of CRKP-infected lesions in a murine model, suggesting its potential as an effective topical treatment. This study highlights BPK01 as a promising biotherapeutic candidate for treating CRKP infection, with the phage hydrogel offering an ecofriendly and sustainable solution for treating infected lesions. Further research could expand its use in phage cocktails and other formulations for broader CRKP infection management.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijbiomac.2025.140887 | DOI Listing |
Indian J Gastroenterol
March 2025
Departments of Pediatrics, Giza, Egypt.
Background And Objectives: Kasai-portoenterostomy (KPE) is the initial attempt to restore the bile flow and salvage the native liver in biliary atresia (BA) patients. Cholangitis is a frequent complication after KPE and adequate treatment impacts the long-term outcome. The aim of our study is to assess the severity of cholangitis episodes in a cohort of BA patients post KPE, identify the causative agents, using several diagnostic methods, as well as to assess the tolerability and efficacy of our antimicrobial protocol.
View Article and Find Full Text PDFCarbapenem-resistant and virulence plasmid-harboring Klebsiella pneumoniae (pVir-CRKP) has emerged and spread globally, yet clinical investigations from the United States remain limited. We conducted a genomic analysis of 884 unique carbapenem-resistant K. pneumoniae isolates from a multicenter US cohort and identified 6 pVir-CRKP isolates, including 2 sequence type (ST) 23, 2 ST893, and 2 ST11 isolates.
View Article and Find Full Text PDFLab Med
March 2025
Department of Clinical Laboratory, People's Hospital of Dayi County, Chengdu Sichuan, China.
Introduction: Carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP) is a highly pathogenic, drug-resistant, and transmissible "superbug" that causes infections in hospitals and communities. Because of the lack of effective antimicrobial treatment options, morbidity and mortality from CR-hvKP infections have increased dramatically, and outbreaks and the rapid spread of CR-hvKP in hospitals have become a major global public health challenge.
Methods: The mechanisms of molecular evolution in CR-hvKP include the acquisition of a hypervirulent plasmid encoding a virulence gene by carbapenemase-producing K pneumoniae, the horizontal transfer of plasmids carrying carbapenem resistance genes to hvKP, and the acquisition of fusion plasmids carrying both carbapenem resistance genes and hypervirulent genes by classic K pneumoniae.
Eur J Immunol
March 2025
Blacktown Clinical School, Western Sydney University, Sydney, NSW, Australia.
Bacteriophages (phages) are emerging as a viable adjunct to antibiotics for the treatment of multidrug-resistant (MDR) bacterial infections. While intravenous phage therapy has proven successful in many cases, clinical outcomes remain uncertain due to a limited understanding of host response to phages. In this study, we conducted a comprehensive examination of the interaction between clinical-grade phages used to treat MDR Escherichia coli and Klebsiella pneumoniae infections, and human peripheral blood immune cells.
View Article and Find Full Text PDFOpen Forum Infect Dis
December 2024
Institute for Infection and Immunity, St George's University of London, London, UK.
Background: Every year an estimated 2-3 million babies are stillborn, with a high burden in Africa. Infection is an important driver of stillbirth. There is a lack of data on the bacterial causes of stillbirth in Uganda, contributing to a lack of interventions such as effective prophylaxis and development of maternal vaccine options against the most implicated pathogens.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!